Der var ingen klinisk signifikant forskel mellem nateglinid’ s systemiske tilgængelighed og halveringstid hos diabetikere med let, moderat (kreatininclearance 31– 50 ml/ min) og svært (kreatininclearance 15– 30 ml/ min) nedsat nyrefunktion (ikke i dialyse) og hos raske personer.
The systemic availability and half-life of nateglinide in diabetic patients with mild, moderate (creatinine clearance 31– 50 ml/ min) and severe (creatinine clearance 15– 30 ml/ min) renal impairment (not undergoing dialysis) did not differ to a clinically significant degree from those in healthy subjects.